极早产儿出生时稳定期呼吸功能监测的多中心随机对照试验
该非盲法多中心RCT纳入288例胎龄24-27周、出生时接受PPV的极早产儿,随机分为RFM屏幕可见组与不可见组,主要终点为手动PPV(面罩或插管)中呼气潮气量(Vte)在4-8 mL/kg目标范围内充气百分比的中位数。结果显示RFM可见组与不可见组分别为30.0%与30.2%(p=0.721),无差异;其他呼吸功能测量、氧饱和度、心率和FiO2均无差异。p=0.028)。
要点
- 在24-27周极早产儿出生时PPV中,RFM可见组Vte在4-8 mL/kg目标范围内的充气百分比中位数为30.0%,未高于RFM不可见组的30.2%(p=0.721)。
- RFM使用未改善其他呼吸功能测量、氧饱和度、心率或FiO2。
- 除IVH和/或囊性PVL外,其他临床结局无差异。
- 该试验为非盲法设计,主要终点未显示RFM指导潮气量输送的优势。
适用人群与场景
- 胎龄24-27周、出生时接受正压通气(PPV)的极早产儿,在7个新生儿重症监护病房(6个国家)中纳入。
诊断标准与关键阈值
- 主要终点为手动PPV(面罩或插管)期间呼气潮气量(Vte)在预设目标范围4-8 mL/kg内的充气百分比中位数。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 非盲法随机对照试验,纳入288例极早产儿(中位胎龄26+2周,IQR 25+3-27+1),共分析51,352次充气。
- RFM可见组Vte在目标范围内的充气百分比中位数为30.0%(IQR 18.0-42.2%),RFM不可见组为30.2%(IQR 14.8-43.1%),p=0.721。
- 其他呼吸功能测量、氧饱和度、心率和FiO2均无差异。
- 除IVH和/或囊性PVL外,其他临床结局无差异。
证据类型、等级与局限
- 多中心随机对照试验(RCT),非盲法设计;样本量288例,7个中心,6个国家;主要终点未显示RFM优势,IVH/囊性PVL为次要结局且p=0.028,需谨慎解读。
对床旁实践的改变
- 在极早产儿出生时PPV中,使用RFM指导潮气量输送未增加Vte在4-8 mL/kg目标范围内的充气比例,不应期望通过RFM提高达标率。
- RFM使用与IVH和/或囊性PVL发生率降低相关(26.7% vs 39.0%),但该结果为次要终点,需进一步验证。
指南或共识出处
- Dutch Trial Register NTR4104;clinicaltrials.gov NCT03256578
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To determine whether the use of a respiratory function monitor (RFM) during PPV of extremely preterm infants at birth, compared with no RFM, leads to an increase in percentage of inflations with an expiratory tidal volume (Vte) within a predefined target range.
METHODS: Unmasked, randomised clinical trial conducted October 2013 - May 2019 in 7 neonatal intensive care units in 6 countries. Very preterm infants (24-27 weeks of gestation) receiving PPV at birth were randomised to have a RFM screen visible or not. The primary outcome was the median proportion of inflations during manual PPV (face mask or intubated) within the target range (Vte 4-8 mL/kg). There were 42 other prespecified monitor measurements and clinical outcomes.
RESULTS: Among 288 infants randomised (median (IQR) gestational age 26+2 (25+3-27+1) weeks), a total number of 51,352 inflations were analysed. The median (IQR) percentage of inflations within the target range in the RFM visible group was 30.0 (18.0-42.2)% vs 30.2 (14.8-43.1)% in the RFM non-visible group (p = 0.721). There were no differences in other respiratory function measurements, oxygen saturation, heart rate or FiO2. There were no differences in clinical outcomes, except for the incidence of intraventricular haemorrhage (all grades) and/or cystic periventricular leukomalacia (visible RFM: 26.7% vs non-visible RFM: 39.0%; RR 0.71 (0.68-0.97); p = 0.028).
CONCLUSION: In very preterm infants receiving PPV at birth, the use of a RFM, compared to no RFM as guidance for tidal volume delivery, did not increase the percentage of inflations in a predefined target range.
TRIAL REGISTRATION: Dutch Trial Register NTR4104, clinicaltrials.gov NCT03256578.
参考来源
- van Zanten HA, Kuypers KLAM, van Zwet EW, et al. A multi-centre randomised controlled trial of respiratory function monitoring during stabilisation of very preterm infants at birth. Resuscitation. 2021. PMID: 34302924. doi:10.1016/j.resuscitation.2021.07.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。